PAG
ZVRA icon

Private Advisor Group’s Zevra Therapeutics ZVRA Stock Holding History

Private Advisor Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,790
Closed -$67K – 1991
2022
Q3 		$67K Hold
10,790
– – ﹤0.01% 1819
2022
Q2 		$48K Hold
10,790
– – ﹤0.01% 2011
2022
Q1 		$54K Sell
10,790
-136
-1% -$865 ﹤0.01% 2038
2021
Q4 		$95K Buy
10,926
+136
+1% +$1.21K ﹤0.01% 2028
2021
Q3 		$101K Buy
+10,790
New +$109K ﹤0.01% 1945

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Private Advisor Group's ZVRA Position: Q4 2022 in Review

Private Advisor Group sold out of Zevra Therapeutics (ZVRA) in Q4 2022, closing a stake of 10,790 shares — an estimated $67K sold.

Private Advisor Group first reported a position in ZVRA in Q3 2021 and held it in 5 quarters. The position peaked at $101K in Q3 2021. 69 funds tracked by Wall St. Rank hold ZVRA as of Q4 2022.

  • Private Advisor Group reported no remaining Zevra Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Private Advisor Group sold 10,790 Zevra Therapeutics shares in Q4 2022, an estimated $67K.
  • Private Advisor Group first reported a position in Zevra Therapeutics in Q3 2021 and held it in 5 quarters.
  • Private Advisor Group's Zevra Therapeutics position peaked at $101K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2022.

Based on Private Advisor Group's 13F filing for Q4 2022, filed 18 Jan 2023.